Lv6
2310 积分 2023-10-09 加入
HPR27 US Food and Drug Administration Approvals, Regulatory Pathways, and Review Time of New Drugs and Biologics, 1980–2024
3个月前
已完结
HPR27 US Food and Drug Administration Approvals, Regulatory Pathways, and Review Time of New Drugs and Biologics, 1980–2024
3个月前
已完结
Reforming the Prescription Drug User Fee Program
3个月前
已完结
Impact of Rule 11 on the European Medical Software Landscape: Analysis of EUDAMED and Further Databases Three Years After MDR Implementation
4个月前
已完结
The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
1年前
已完结
Analysis Of Cell Balancing Techniques In BMS For Electric Vehicle
1年前
已完结
Regulatory strategies for biomaterials and medical devices in the USA: classification, design, and risk analysis
1年前
已完结
NICE and value based pricing: what do we know?
1年前
已完结
NICE and value based pricing: what do we know?
1年前
已关闭
皖公网安备34019202002308
